tHEORetically Speaking – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

tHEORetically Speaking

HealthEconomics.com

Science

Frequency: 1 episode/17d. Total Eps: 87

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Read moreCollapse

Site

RSS

Apple

Data updated on 03/08/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇬🇧 Great Britain - Life Sciences
11/06/2026
#88
🇬🇧 Great Britain - Life Sciences
10/06/2026
#77
🇬🇧 Great Britain - Life Sciences
09/06/2026
#57
🇬🇧 Great Britain - Life Sciences
08/06/2026
#40
🇬🇧 Great Britain - Life Sciences
07/06/2026
#24
🇬🇧 Great Britain - Life Sciences
26/04/2026
#86
🇬🇧 Great Britain - Life Sciences
25/04/2026
#68
🇬🇧 Great Britain - Life Sciences
24/04/2026
#56
🇬🇧 Great Britain - Life Sciences
23/04/2026
#44
🇬🇧 Great Britain - Life Sciences
22/04/2026
#22

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.trialinsights.com/
9 shares
https://www.terrapinn.com/EPA/2026/HealthEconomics
4 shares
https://www.metliconsulting.com/
3 shares

https://www.linkedin.com/company/healtheconomics-com/
4 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 58%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap

Season 5 · Episode 17

Monday, July 13, 2026 • Duration 11:42

In this episode of tHEORetically Speaking, we sit down with Becky Hollenberg, MPH, Senior RWD Strategy Lead at Norstella, to explore why data access is no longer the ultimate differentiator. Instead, the true competitive edge lies in evidence usability—the ability to connect clinical context, lab values, unstructured clinical notes, and payer policy into a single, cohesive narrative.

Learn more about Norstella: www.norstella.com

Read moreCollapse

Weekly News Roundup — Wegovy Pill’s Historic Debut, Lilly’s Manufacturing Expansion, and Robotic GI Breakthroughs

Season 5 · Episode 16

Friday, May 8, 2026 • Duration 03:32

This week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s oral Wegovy pill shattering market expectations with $355 million in first-quarter sales, and Eli Lilly’s massive $4.5 billion investment to expand its manufacturing footprint in Indiana. We also explore Neptune Medical’s Triton GI robot reaching major clinical milestones in its first-in-human trials.

Tune in for this concise recap of these pivotal industry updates!

Read moreCollapse

Weekly News Roundup — Real-Time Clinical Trials, Canadian Breast Cancer Standards, and FDA Data Integrity Concerns

Season 5 · Episode 15

Friday, May 1, 2026 • Duration 04:37

This week’s tHEORetically Speaking News Roundup covers the FDA’s new real-time clinical trial initiative utilizing AI for faster drug development, and Breast Cancer Canada’s new unified national recommendations to eliminate regional disparities in care. We also break down the FDA’s proposal to withdraw Amgen’s Tavneos over data integrity issues and safety concerns.

Use code HE25 for an extra 25% off your registration fee!

Read moreCollapse

INsights & OUTcomes with Mark Larkin

Season 5 · Episode 14

Monday, April 20, 2026 • Duration 29:00

On this episode of INsights & OUTcomes, we sit down with Mark Larkin, real-world evidence expert at Vitaccess, to explore why the "gold standard" of clinical trials often falls short the moment a treatment hits the real world.

We dive deep into the shift toward patient-centered science, discussing the critical difference between a study that is truly patient-centric versus one that is merely "patient-advised." Mark explains how longitudinal data is filling the gaps left by RCTs, from capturing the granular daily impacts of rare diseases to understanding the ripple effect of treatments on caregivers.

Watch the full conversation here: https://youtu.be/ApKzubFy4Ao

Read moreCollapse

Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal

Season 5 · Episode 13

Friday, April 10, 2026 • Duration 03:49

This week’s tHEORetically Speaking News Roundup covers Steve Ubl’s planned departure from PhRMA after a decade of navigating the industry through landmark legislative shifts, and the growing momentum of ICHRAs as employers move toward "defined contribution" healthcare models. We also break down the preliminary MDUFA VI agreement, which signals a major hiring push at the FDA and a new "America-First" fee structure for medtech.

Tune in for this concise recap of these pivotal industry updates!

Read moreCollapse

Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock

Season 5 · Episode 13

Friday, March 27, 2026 • Duration 02:40

This week’s tHEORetically Speaking News Roundup covers Abbott’s $21 billion acquisition of Exact Sciences, signaling a major expansion in cancer diagnostics, and Boehringer Ingelheim’s concerns over Europe’s slowing regulatory timelines compared to the U.S. We also break down a global supply chain shock triggered by the Strait of Hormuz closure.

Tune in for this concise recap of these pivotal industry updates!

Read moreCollapse

Weekly News Roundup — Medicaid Maternal Care Expansion, Breakthrough Diabetes Data, and SMA Market Shakeups

Season 5 · Episode 12

Friday, March 20, 2026 • Duration 02:31

This week’s tHEORetically Speaking News Roundup covers Nadia Care’s $12M raise to expand Medicaid-focused maternal care, Eli Lilly’s breakthrough Phase 3 results for its triple agonist retatrutide in type 2 diabetes, and Roche’s decision to halt development of its SMA therapy—reshaping competition in the rare disease space.

Tune in for this concise recap of the key developments shaping the HEOR, RWE, and market access landscape.

Read moreCollapse

Weekly News Roundup — Biosimilar Policy Changes, mRNA Leadership Shifts, and Rare Disease Market Growth

Season 5 · Episode 11

Friday, March 13, 2026 • Duration 04:07

This week’s tHEORetically Speaking News Roundup covers the FDA’s new guidance aimed at streamlining biosimilar development and reducing drug costs, leadership changes at BioNTech as its founders step down to launch a new mRNA venture, and projections that the global rare disease drug market could surpass $400 billion by 2032. We also explore the FDA’s launch of a new unified adverse event monitoring platform designed to modernize safety surveillance and improve transparency.

Tune in for this concise recap of the key developments shaping the life sciences, HEOR, and market access landscape.

Read moreCollapse

Weekly News Roundup — mRNA Vaccine Milestones, Obesity Drug Manufacturing, and Gene Therapy Regulatory Tensions

Season 5 · Episode 10

Friday, March 6, 2026 • Duration 03:58

This week’s tHEORetically Speaking News Roundup covers Moderna’s progress toward European approval of its combination COVID-19 and flu mRNA vaccine, Novo Nordisk’s $501 million investment to expand Wegovy pill production in Ireland, and Moderna’s $2.25 billion settlement resolving a major mRNA patent dispute. We also explore the FDA’s disagreement with uniQure over clinical trial requirements for its Huntington’s gene therapy.

Tune in for this concise recap of the key developments shaping the life sciences and market access landscape.

Read moreCollapse

INsights & OUTcomes with Radek Wasiak

Season 5 · Episode 9

Friday, February 27, 2026 • Duration 25:43

This episode features Radek Wasiak, an expert in real world data generation, and real-world evidence. He has provided research services to the life sciences for more than two decades and is currently the director of Adigens Health.

This chat wasn't just a technical deep dive; it was a journey through the past, present, and future of how we prove medicine actually works, and highlights the high-stakes world of Real-World Evidence (RWE).

To watch the full interview, click here!

Learn more about Adigens Health: https://www.adigenshealth.com/

Adigens Health partners with life sciences companies to harness insights and real-world evidence to expedite clinical development and effectively prepare for asset launch.

Read moreCollapse

tHEORetically Speaking – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

tHEORetically Speaking – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other99+

LinkedIn1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other99+

LinkedIn1

Youtube1